Estrogens reduce plasma histidine-rich glycoprotein (HRG) levels in a dose-dependent way
article
Plasma levels of histidine-rich glycoprotein (HRG) were investigated in three groups of women receiving a different dose of estrogens. First, the effect of low-dose estrogen was studied in a group of 83 postmenopausal women who were treated with 0.625 mg conjugated estrogens (CE). No significant change from baseline levels was found at the end of cycle 3 and cycle 13. Secondly, in 15 mothers and 23 daughters using oral contraceptives (OC) containing 30-50 μg ethinyl estradiol (EE) daily the mean HRG level was 14% and 24% lower than in a group of 144 mothers and 134 daughters not taking oral contraceptives, respectively (p < 0.05). Finally, in 11 excessively tall prepuberal girls who received 300 μg EE daily to reduce their final height the mean plasma HRG levels were decreased by 68% (p < 0.005). The effect of progestogens administered during low-dose and high-dose estrogen therapy appeared to be minor. The results from these three studies indicate that estrogens reduce plasma HRG levels in a dose-dependent way. Chemicals/CAS: ethinylestradiol, 57-63-6; histidine, 645-35-2, 7006-35-1, 71-00-1; medrogestone, 977-79-7; Contraceptives, Oral, Hormonal; Estrogens, Conjugated; Ethinyl Estradiol, 57-63-6; histidine-rich proteins; Medrogestone, 977-79-7; Medroxyprogesterone 17-Acetate, 71-58-9; Proteins
Topics
TNO Identifier
232915
ISSN
03406245
Source
Thrombosis and Haemostasis, 73(3), pp. 484-487.
Pages
484-487
Files
To receive the publication files, please send an e-mail request to TNO Repository.